Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

As the world anxiously awaits COVID-19 vaccines, people working in healthcare settings remain at risk of infection from COVID-19. The Pakistani arm of COPCOV, the global study to test if hydroxychloroquine or chloroquine can prevent COVID-19 in healthcare workers, has begun to enrol participants at Aga Khan University, joining sites in the UK and Thailand.

Pakistan Principal Investigator Prof. M. Asim Beg and two colleagues in a hospital setting.

On 17 Nov, the Pakistan arm of COPCOV enrolled its first participant at Aga Khan University (AKU), Karachi, as COPCOV Pakistan PI Prof. M. Asim Beg looked on. Prof. Beg will be supported by AKU’s Drs Farah Qamar, Faisal Mahmood, Noshin Nasir, Momin Qazi, Sonia Qureshi and Najia Ghanchi as well as Prof. Saeed Hamid, director of AKU’s Clinical Trials Unit.

Pakistan joins Thailand and COPCOV UK sites in participating in COPCOV, the MORU-led, Oxford-supported global study to test if hydroxychloroquine or chloroquine can prevent COVID-19 in healthcare workers. AKU expects to enrol 400 participants, with new COPCOV sites in Indonesia and Kenya expected to begin enrolment in late Nov-early Dec.

Send us an enquiry if you are interested in setting up a COPCOV clinical study site in your country.

Similar stories

Lack of evidence is key barrier to using portable devices to detect poor quality medicines

A series of papers which reviewed portable devices to detect poor quality medicines has concluded major gaps in scientific evidence remain a key barrier for regulators to implement surveillance systems using such devices.

Tropical Medicine DPhil Students awarded NDM Prize

Every year, the Nuffield Department of Medicine awards NDM Prizes to our most outstanding students. This year, Mo yin and Rebecca Inglis (both at MORU) were highly commended in the category NDM Overall Prize, for conducting research with an outstanding impact. Will Schilling (MORU) received a prize as first year DPhil student, and Mohammad Ali (OCGHR) as second year DPhil student. Our warmest congratulations to you all!

New study alerts to the risk of poor quality medicines used to prevent and treat cardiovascular disease

There are important but neglected issues with substandard and falsified medicines and medical products used to prevent and treat cardiovascular diseases. From limited available data, MORU and IDDO scientists found about one fifth of medicines reported as sampled in the literature were substandard or falsified. This systematic review suggests that more and better quality data and data sharing are needed to better understand the global burden of this problem and inform interventions.

Congratulations new Associate Professors

Following the meeting of the Medical Sciences Divisional Committee to consider applications for the conferral of the title of Associate Professor, we are pleased to announce that Rashan Haniffa, Dorcas Kamuya, Isabella Oyier, Le Van Tan and Timothy Walker have been awarded the title Associate Professor

COPCOV now world’s largest COVID-19 pre-exposure prophylaxis trial

A 6-week recruitment burst at Aga Khan University in Pakistan led the way as COPCOV enrolment broke 1600 participants. Led by MORU, COPCOV is the world’s largest trial trying to determine if hydroxychloroquine and chloroquine prevent COVID-19.

How did people in Europe and SE Asia experience the first COVID-19 wave?

An international team, led by Phaik Yeong Cheah, conducted an anonymous online survey from May-June 2020, asking 5,058 people in Thailand, Malaysia, United Kingdom, Italy and Slovenia to share their experiences. Anne Osterrieder and colleagues report the unequal impacts of public health measures, and the prevalence of ‘fake news’.